Publication at First Faculty of Medicine |
2015
Abstract
Routine recommendations for the intensification of insulin therapy include the use of basal-plus event. basal-bolus therapy which combine basal insulin administration with prandial insulin. These schemes, however, are usually accompanied by weight gain and the occurrence hypoglycemia, which also adversely affects the adherence to treatment.
Lixisenatide receptor agonist is GLP-1 (glucagon-like peptide-1), which can be referred by currently valid recommendations used in combination with basal insulin as alternative administration prandial insulin in patients with type 2 diabetes mellittus, where the basal insulin therapy fail to control the disease.